Updated:
Alvotech
Róbert Wessman's Alvotech develops and manufactures interchangeable biosimilars including a Humira challenger approved by the FDA in 2024.
Alvotech
Alvotech was founded in Reykjavík in 2013 by pharmaceutical entrepreneur Róbert Wessman, following the $2.7 billion sale of his generics platform Alvogen. The company was purpose-built to industrialize the risky, high-cost business of biosimilar development. Wessman, who chairs the firm, installed former Mylan executive Mark Levick as CEO to scale manufacturing across a 200,000-square-foot facility near Reykjavík Science Park, which remains the operational core. The firm operates as an integrated biosimilar developer and manufacturer, holding its own reference-drug originator biologics license. Its pipeline spans immunology, oncology, and ophthalmology. The signature asset is AVT02, a high-concentration, citrate-free adalimumab biosimilar referencing Humira, which gained FDA interchangeable designation in 2024. The global commercialization partnership with Teva covers the US market, while Stada handles marketing across multiple European territories. Additional disclosed programs target Stelara (ustekinumab), Simponi (golimumab), and Eylea (aflibercept), among others. Alvotech went public via a SPAC merger with Oaktree-backed OACB at an enterprise value of roughly $2.25 billion, introducing its shares on Nasdaq Iceland and Nasdaq New York in June 2022. The company employs a multi-partner commercialization model rather than constructing a global salesforce, preferring to co-invest with regional distributors and established pharma players. A secondary manufacturing site expansion in Hannover, Germany was announced to supplement Icelandic capacity, with a targeted operational date in 2025. Structurally, Alvotech is a public pharmaceutical company that acts as a dedicated pure-play biosimilar engine — a rarity in a segment dominated by conglomerate divisions in Pfizer, Novartis, and Amgen. Wessman retains substantial founder control through a rolling holding company structure known in Nordic markets, insulating long-horizon biosimilar R&D from quarterly earnings pressure despite the Nasdaq listing.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
Europe
Country
Iceland
City
Reykjavík
Corporate office
Reykjavík, Iceland
Additional offices
Morristown, New Jersey, United States
Principals
Róbert Wessman
Founder & Executive Chairman
Mark Levick
CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Alvotech?
Alvotech is not a fund or investment vehicle — it is a Nasdaq-listed operating pharmaceutical company. R&D allocation and commercialization strategy are driven by the executive team led by CEO Mark Levick and Chairman Róbert Wessman. Capital allocation decisions — including its SPAC merger and subsequent equity raises — are executed under Board supervision. The firm does not operate an external LP capital pool.
How does the commercial partnership with Teva function?
Alvotech and Teva entered a strategic partnership in August 2020 granting Teva exclusive US commercialization rights to AVT02, Alvotech's Humira biosimilar. The deal structure shares profit rather than relying on a traditional royalty model. Teva invested capital into Alvotech and assumed responsibility for US sales, marketing, and reimbursement access, while Alvotech handles development, manufacturing, and regulatory filing.
Is Alvotech structured as a family office or a traditional pharma company?
Alvotech is a publicly listed specialty pharmaceutical company — not a family office, venture firm, or fund — that concentrates exclusively on biosimilars. Its Nasdaq listing and SPAC merger route make it an operational entity rather than an investment platform, though founder Róbert Wessman retains significant governance influence through a multi-tiered Nordic holding structure.
What biosimilar pipeline assets has Alvotech disclosed?
Publicly disclosed programs include AVT02 (adalimumab, referencing Humira), AVT04 (ustekinumab, referencing Stelara), AVT05 (golimumab, referencing Simponi), AVT06 (aflibercept, referencing Eylea), AVT03 (denosumab, referencing Prolia/Xgeva), and AVT23 (omalizumab, referencing Xolair). Several assets are in Phase III or under regulatory review across US, EU, and other major markets (per the firm).
Where does Alvotech manufacture its biosimilars?
Primary manufacturing is conducted at Alvotech's dedicated facility near Reykjavík Science Park in Iceland, which houses cell culture, purification, and fill-finish lines within a single campus. In 2023 the company announced a secondary fill-finish site in Hannover, Germany to support expanded capacity and EU distribution redundancy, with expected operational readiness in 2025 (per the firm).
Why did Alvotech choose a SPAC rather than a traditional IPO?
The SPAC structure — a merger with Oaktree Capital Management-backed OACB in June 2022 — provided Alvotech a faster route to public markets and unlocked committed PIPE funding to support the build-out of its manufacturing capacity. The transaction gave the firm an enterprise value of roughly $2.25 billion at closing and listed shares on both Nasdaq Iceland and the Nasdaq Global Select Market in New York.
What is Róbert Wessman's track record before Alvotech?
Wessman founded generic pharmaceutical company Alvogen in 2009 and grew it into a global operation before selling a controlling stake to CVC Capital Partners in a deal that valued the company at approximately $2.7 billion. Prior to Alvogen, he led Actavis Group — not the US firm — from 1999 until its 2007 sale to Watson Pharmaceuticals. His entire career has been focused on building complex generic and biosimilar manufacturing platforms from Iceland outward.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: